Back
Entrada Therapeutics Quote, Financials, Valuation and Earnings
Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term
See if stocks could soar as much as 1,000% if history repeats itself.
Buy
55
TRDA
Entrada Therapeutics
Last Price:
17.81
Seasonality Move:
-29.61%
7 Day Trial
ALL ACCESS PASS
$
7
America's enemies are regrouping & it may sucker punch your savings
Click here to learn more.Entrada Therapeutics Price Quote
$17.81
-0.04 (-6.46%)
(Updated: November 16, 2024 at 5:42 AM ET)
Entrada Therapeutics Key Stats
Buy
55
Entrada Therapeutics (TRDA)
is a Buy
Day range:
$17.71 - $19.23
52-week range:
$10.75 - $20.49
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3.19
P/B ratio:
1.69%
Volume:
140.7K
Avg. volume:
131.1K
1-year change:
9.24%
Market cap:
$712.2M
Revenue:
$129M
EPS:
$1.59
How Much Does Entrada Therapeutics Make?
-
How Much Are Entrada Therapeutics's Sales Annually?
TRDA Revenues are $129M -
How Much Profit Does Entrada Therapeutics's Make A Year?
TRDA net income is -$6.7M
Is Entrada Therapeutics Growing As A Company?
-
What Is Entrada Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.55% -
What Is Entrada Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Entrada Therapeutics Stock Price Performance
-
Did Entrada Therapeutics Stock Go Up Last Month?
Entrada Therapeutics share price went up by 1.83% last month -
Did TRDA's Share Price Rise Over The Last Year?
TRDA share price rose by 9.24% over the past 1 year
What Is Entrada Therapeutics 52-Week High & Low?
-
What Is Entrada Therapeutics’s 52-Week High Share Price?
Entrada Therapeutics has traded as high as $20.49 over the past 52 weeks -
What Is Entrada Therapeutics’s 52-Week Low Share Price?
Entrada Therapeutics has traded as low as $10.75 over the past 52 weeks
Entrada Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Entrada Therapeutics?
-
How Much Debt Does Entrada Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Entrada Therapeutics Have?
Cash and short term investments quarterly total is $449.3M -
What Is Entrada Therapeutics’s Book Value Per Share?
Book value per share is 11.30
Is Entrada Therapeutics Cash Flow Positive?
-
What Is TRDA Cash Flow From Operations?
Cash flow from operations (TTM) is -$14M -
What Is Entrada Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $102.3M -
What Is Entrada Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$62.1M
Entrada Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
TRDA return on invested capital is 17.06% -
What Is Entrada Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 10.56% -
What Is TRDA Return On Equity?
ROE is a measure of profitability and is 17.06%
Entrada Therapeutics Earnings Date & Stock Price
-
What Is Entrada Therapeutics's Stock Price Today?
A single share of TRDA can be purchased today for 17.85 -
What Is Entrada Therapeutics’s Stock Symbol?
Entrada Therapeutics trades on the nasdaq under the ticker symbol: TRDA -
When Is Entrada Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Entrada Therapeutics is scheduled on March 13, 2025 -
When Is TRDA's next ex-dividend date?
Entrada Therapeutics's next ex-dividend date is November 16, 2024 -
How To Buy Entrada Therapeutics Stock?
You can buy Entrada Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Entrada Therapeutics Competitors
-
Who Are Entrada Therapeutics's Competitors?
Below is a list of companies who compete with Entrada Therapeutics or are related in some way:
Entrada Therapeutics Dividend Yield
-
What Is TRDA Dividend Yield?
Entrada Therapeutics’s dividend yield currently is 0% -
What Is Entrada Therapeutics’s Payout Ratio?
Entrada Therapeutics’s payout ratio is 0% -
When Did Entrada Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 16, 2024 -
What Is Entrada Therapeutics’s Dividend Per Share?
Entrada Therapeutics pays a dividend of $0.00 per share
Entrada Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 44% |
| Revenue: | -55.25% | 64.8% |
Analyst Recommendations
| Buy Recommendations: | 4 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 25.57 |
| Upside from Last Price: | 43.25% |